Doceree Dialogue Episode 8: Powering Precision HCP Engagement Through Real-World Data — A Conversation with Scott Phillips
In the latest episode of Doceree Dialogue, Julius Ramirez, EVP & GM, Data & Partnerships, Doceree sat down with Scott Phillips, Vice President, Real World Data, Diaceutics PLC, for an in-depth conversation on the future of data-powered physician engagement.
With nearly two decades of experience across real-world evidence, product development, AI-driven modeling, and clinical data strategy, Scott brings a practitioner’s perspective to a market rapidly reshaped by precision medicine and multimodal intelligence.
From Data Scarcity to Data Abundance — and the Opportunities Ahead
Scott began by reflecting on how dramatically the real-world data landscape has evolved.
“When I started, the biggest challenge wasn’t how to use data — it was simply finding it,” he shared.
“Today, there is a treasure trove. The question is no longer access, but how we meaningfully connect and activate it.”
Yet even in this era of abundance, Scott believes the industry is still missing a unified view of the patient—primarily because many organizations still anchor decisions on claims data alone.
“Claims data is incredibly important,” he noted. “But it’s only one piece of the puzzle. EMR, genomics, lab data, SDoH — all of this adds richness and completes the patient story.”
What Makes Diaceutics Different
As Scott explained, Diaceutics was built to bring that patient story into full view.
Their network - the DXRX platform — aggregates, normalizes, and standardizes clinical lab and genomic data from more than 600 labs across the U.S. This multimodal dataset is then blended using AI with claims, EMR and prescription data to form a complete, longitudinal understanding of each patient’s journey.
While Diaceutics is known for its leadership in oncology and rare disease, Scott emphasized that their framework can now support any therapeutic category that benefits from precise, genetic- or biomarker-driven insights.
“Our goal is to help pharmaceutical companies understand who is being treated, when, and how, in the most clinically relevant way possible.”
Rethinking HCP Targeting in a Precision Medicine Era
The conversation naturally transitioned to the intersection between this data and HCP engagement.
For Scott, precision starts with rejecting outdated assumptions:
“Not all diabetes is the same. Not all hypertension is the same. Precision medicine is about getting to an N of 1—how do we treat the unique patient in front of the physician at that moment?”
Through lab and genomic signals, Diaceutics helps identify:
- Physicians treating uncontrolled vs. controlled diabetics
- HCPs managing pre-diabetic populations
- Clinicians actively treating patients who have the disease but show no corresponding claim
- Providers who are under-recognized due to blind spots in claims-derived cohorts
This “hidden treater” phenomenon is one of the biggest gaps in traditional targeting.
“A claim doesn’t mean a diagnosis. And the absence of a claim doesn’t mean the absence of disease,” Scott stressed.
“The only way to truly understand the patient is to look at the clinical data.”
How This Data Translates to HCP Messaging
As marketers think about activating campaigns, Scott offered clear advice:
“You start with the use case. Claims data might be enough for broad, directional targeting. But if you need precision — if you need to know exactly which patients a doctor is seeing at this moment — that requires deeper clinical and genomic data.”
He also cautioned against extremes:
“Too much targeting can limit scale. Too little can dilute impact. The balance comes from understanding the brand objective and selecting the right data layers accordingly.”
The Doceree–Diaceutics Partnership: Powering Real-Time Clinical Relevance
At Doceree, this philosophy aligns closely with how we think about point-of-care engagement.
Everything we deliver inside the EHR is designed around real-time clinical relevance, the right message, and the exact moment of care. Diaceutics’ patient-level multimodal intelligence strengthens this mission.
“Partners like Doceree are critical,” Scott said.
“You’re directly inside the EMR. You’re at the point of decision. By combining that moment with more precise data, we can ensure that every patient has the opportunity to get on the right drug at the right time.”
For Scott, the motivation behind the partnership is simple:
“At the end of the day, we all do this work because we want to help patients. This ecosystem makes that possible.”
If Scott Had One Superpower to Transform HCP Engagement…
His answer was immediate: “More data.”
With AI accelerating the need for richer signals, Scott believes that the future of effective physician engagement rests on the depth, diversity, and real-time availability of structured clinical data.
“The more data you have, the better the insights. And the closer you get to that N of 1, where you know the best treatment for that individual patient at that exact moment in their journey.”
Closing Thoughts
Our conversation with Scott Phillips illuminated a crucial truth:
As the industry steers toward precision medicine, the power of HCP engagement will depend on how intelligently we combine data depth, workflow integration, and real-time activation.
Through partnerships like the one between Diaceutics and Doceree, that future is already taking shape - bringing clinical context, patient-level insights, and actionable intelligence directly into the point of care.
Stay tuned for more episodes of Doceree Dialogue, where we continue exploring the people, partnerships, and innovations reshaping the future of healthcare marketing.